The coffee company announced three Houston-area solar projects. Courtesy of Starbucks

Coffee shop chain Starbucks is plugging into Texas' solar energy industry in a big way.

Two 10-megawatt solar farms in Texas owned by Cypress Creek Renewables LLC are providing enough energy for the equivalent of 360 Starbuck stores, including locations in Houston, Humble, Katy, and Spring. Separately, Starbucks has invested in six other Texas solar farms owned by Cypress Creek, representing 50 megawatts of solar energy; Santa Monica, California-based Cypress Creek is selling that power to other customers.

Three of the eight solar farms in the Texas portfolio are just outside the Houston metro area. One is in the Fort Bend County town of Beasley, while two of the projects are in Wallis and Wharton.

Starbucks already relies on a North Carolina solar farm equipped with 149,000 panels to deliver solar energy equivalent to powering 600 Starbucks stores in North Carolina, Delaware, Kentucky, Maryland, Virginia, West Virginia, and Washington, D.C.

"Our long-standing commitment to renewable energy supports our greener-retail initiative and demonstrates our aspiration to sustainable coffee, served sustainably," Rebecca Zimmer, Starbucks' director of global environmental impact, says in an April 15 release about its solar investment in Texas. "Now, we are investing in new, renewable energy projects in our store communities, which we know is something our partners and customers can appreciate for their local economy and for the environment."

The solar commitment in Texas aligns with Starbucks' goal of designing, building, and operating 10,000 "greener" company-owned stores around the world by 2025. The Seattle-based retailer expects this initiative — whose features include renewable energy, energy efficiency, and waste reduction — to cut $50 million in utility costs over the next 10 years.

U.S. Bank's community development division teamed up with Starbucks and Cypress Creek on the Texas solar farms. Chris Roetheli, a business development officer at U.S. Bank, says solar tax equity investments like those undertaken by Starbucks are growing in popularity among non-traditional investors.

"Starbucks is taking a unique approach — investing in solar farms regionally to support a specific group of its stores," Roetheli says in the announcement of the solar collaboration. "This is a new concept, and one that I think other companies are watching and may follow. It's an interesting model that allows them to talk specifically about the impact of their investments."

Starbucks' investment comes as Texas' stature in the solar energy sector keeps rising, along with the state's role in the wind energy industry.

According to the Solar Energy Industries Association, more than 2,900 megawatts of solar capacity are installed in Texas. That's enough energy to power nearly 350,000 homes. Among the states, Texas ranks fifth for the amount of installed solar capacity.

Solar investment in Texas exceeds $4.5 billion, with about 650 solar companies operating statewide, the association says. The solar energy industry employs more than 13,000 full-time and part-time workers in Texas, according to the Texas Solar Power Association.

With more than 4 gigawatts (over 7,000 megawatts) of solar capacity expected to be added in Texas over the next five years, the national solar association reported in 2018 that "Texas is poised to become a nationwide leader in solar energy … ."

As it stands now, though, solar supplies less than 1 percent of Texas' electricity.

A 2018 state-by-state report card for friendliness toward solar power assigned a "C" to Texas, putting it in 34th place among the states.

The report card, released by SolarPowerRocks.com, lauds the backing of big Texas cities like Houston, Austin, Dallas, and San Antonio in encouraging residential solar installations.

However, the report card adds, outlying areas in Texas lag their urban counterparts in support of residential solar, "and we'd like lawmakers here to codify more protections and goals for solar adoption, but in the most populous areas, the Lone Star [State] shines."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.